High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen

Journal of Acquired Immune Deficiency Syndromes

Volumn 29, Issue 4, 2002, Pages 374-377

  Solas, Caroline ^a   Basso, Stéphanie ^a   Poizot Martin, Isabelle ^a   Ravaux, Isabelle ^a   Gallais, Hervé ^a   Gastaut, Jean Albert ^a   Durand, Alain ^a   Lacarelle, Bruno ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Dose adjustment; HAART; Indinavir trough concentration; Toxicity

Indexed keywords

INDINAVIR; RITONAVIR; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; GASTROINTESTINAL TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN TOXICITY; VIRUS LOAD; BLOOD; DRUG COMBINATION; HUMAN IMMUNODEFICIENCY VIRUS 1; VIROLOGY;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; MALE; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; RITONAVIR;

EID: 0036525753     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200204010-00008     Document Type: Article

References (15)

1. Continued indinavir (800mg tid) versus switching to indinavir + ritonavir (800/100mg bid) in HIV patients having achieved viral load suppression: A randomized study: The BID efficacy and safety trial (BEST)
2. Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals
3. DIRECT Study: A multicenter, open-label, 24-week pilot study with a 24-week extension to evaluate the efficacy, safety and tolerability of indinavir (IDV)-ritonavir (RTV) 100/800 bid in combination with d4T plus 3TC in HIV-infected individuals
4. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
5. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents
6. Indinavir concentrations and antiviral effect
7. Pharmacodynamics (PD) of indinavir (IDV) in protease-naive HIV-infected patients receiving ZDV and 3TC
8. Multiple-dose pharmacokinetics (PK) and tolerability of indinavir (IDV)-ritonavir (RTV) combinations in healthy volunteers (Merck 078)
9. Indinavir (IDV) + ritonavir (RTV) bid regimens: Pharmacokinetics (PK), safety and efficacy
10. Pharmacokinetics of an indinavir/ritonavir 800/100mg bid regimen
11. The role of therapeutic drug monitoring in treatment of HIV infection
12. Therapeutic drug monitoring (TDM) of indinavir (IDV) and of nelfinavir (NFV) in treatment-naive patients improves therapeutic outcome after 1 year: Results from ATHENA
13. Simple high-performance liquid chromatographic determination of the protease inhibitor indinavir in human plasma
14. Increasing adverse events (AE) with indinavir (IDV) dosages and plasma concentrations in four different ritonavir (RTV)-IDV containing regimen in HIV infected patients